Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Gonococcal Vaccine Project

A vaccine to prevent gonorrhoea and combat spread of AMR targeting LMICs

GONOCCOCAL VACCINE PROJECT

BACKGROUND

Neisseria gonorrhoeae (gonococcus) causes 82.4 million cases of the sexually transmitted infection, gonorrhoea, annually with women in low- and middle-income countries (LMICs) disproportionately affected. Complications include pelvic inflammatory disease, ectopic pregnancy, infertility, and infant blindness. Rapid emergence of multi-drug resistant gonococci threatens to make these infections untreatable. The need for a gonococcal vaccine is pressing, but currently none is available.

 

Map showing distribution of gonorrhea worldwide. Source: WHOMap showing distribution of gonorrhea worldwide. Source: WHO

 

NEW VACCINE RESEARCH AND PRODUCT DEVELOPMENT

We are using native outer membrane vesicle (nOMV) technology to develop a candidate vaccine against gonococcus, GonoVac. The vaccine is immunogenic and able to accelerate the clearance of gonococcus in a preclinical infection model. We are currently planning a Phase 1 study to test our vaccine in humans.


COLLABORATORS
Professor Christine Rollier 

Christine S. Rollier — The Jenner Institute

University of Surrey 

https://www.surrey.ac.uk/people/christine-rollier

 

Read more about the project funding here  

Sanjay Ram

https://profiles.umassmed.edu/display/133603

 

 

Our team

Recent publications

More publications